[1] ZENG Z, LIN X, ZHENG R, et al. Celastrol alleviates airway hyperresponsiveness and inhibits Th17 responses in obese asthmatic mice[J]. Front Pharmacol, 2018, 9: 49.
[2] ARAGONES G, ARDID-RUIZ A, IBARS M, et al. Modulation of leptin resistance by food compounds[J]. Mol Nutr Food Res, 2016, 60(8): 1789-1803.
[3] LEE J, LIU J, FENG X, et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice[J]. Nat Med, 2016, 22(9): 1023-1032.
[4] LIANG R, LI X, ZHANG R, et al. Acylation of exenatide by glycolic acid and its anti-diabetic activities in db/db mice[J]. Pharm Res, 2014, 31(8):1958-1966.
[5] FERRANTE A W JR. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation[J]. J Intern Med, 2007, 262(4): 408-414.
[6] SPIEZIO S H, AMON L M, MCMILLEN T S, et al. Genetic determinants of atherosclerosis, obesity, and energy balance in consomic mice[J]. Mamm Genome, 2014, 25(11-12): 549-563.
[7] CHEN S R, DAI Y, ZHAO J, et al. A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F[J]. Front Pharmacol, 2018, 9: 104.
[8] ZHOU Z L, YANG Y X, DING J, et al. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms[J]. Nat Prod Rep, 2012,29(4): 457-475.
[9] SU P, GUAN H, ZHAO Y, et al. Identification and functional characterization of diterpene synthases for triptolide biosynthesis from Tripterygium wilfordii[J]. Plant J, 2018, 93(1): 50-65.
[10] HANG H, ZENG Z Y, WANG L, et al. Effect of celastrol on airway inflammation and Th17 cells in obese asthmatic mice[J]. Chin Pharm J(中国药学杂志), 2019, 54(7): 542-548.
[11] SHEN Y F, ZHANG X, WANG Y, et al. Celastrol targets IRAKs to block Toll-like receptor 4-mediated nuclear factor-κB activation[J]. J Integr Med, 2016,14(3): 203-208.
[12] LI H Y, ZHANG J, SUN L, et al. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study[J]. Cell Death Dis, 2015,22(6):e1604.
[13] XIN W, WANG Q, ZHANG D, et al. A new mechanism of inhibition of IL-1β secretion by celastrol through the NLRP3 inflammasome pathway[J]. Eur J Pharmacol, 2017, 814(5):240-247.
[14] LIU B Y, TONG N S, LI Y Y, et al. Hypoglycemmic mechanism of polygonum capitatum extract on spontaneous model of type 2 diabetic db/db mice[J]. Chin Pharm J(中国药学杂志), 2017, 52(5): 384-390.
[15] VAN DOORN C, MACHT V A, GRILLO C A, et al. Leptin resistance and hippocampal behavioral deficits[J]. Physiol Behav, 2017, 1(176):207-213.
[16] LIU J, LEE J, SALAZAR HERNANDEZ M A, et al. Treatment of obesity with celastrol[J]. Cell, 2015,161(5): 999-1011.
[17] GREENHILL C. Celastrol identified as a leptin sensitizer and potential novel treatment for obesity[J]. Nat Rev Endocrinol, 2015, 11(8): 444.
[18] AL-MASHHADI A L, POULSEN C B, VON WACHENFELDT K, et al. Diet-induced abdominal obesity, metabolic changes, and atherosclerosis in hypercholesterolemic minipigs[J]. J Diabet Res, 2018, 2018: 6823193.
[19] CRUNKHORN S. Metabolic disease: leptin sensitizer reverses obesity[J]. Nat Rev Drug Discov, 2016,15(9): 601.
[20] FENG X, GUAN D, AUEN T, et al. IL1R1 is required for celastrol's leptin-sensitization and antiobesity effects[J]. Nat Med, 2019.
[21] KYRIAKOU E, SCHMIDT S, DODD G T, et al. Celastrol promotes weight loss in diet-induced obesity by inhibiting the protein tyrosine phosphatases PTP1B and TCPTP in the hypothalamus[J]. J Med Chem, 2018, 61(24):11144-11157.
[22] POLEDNE R, LESNA I K. Inflammation and atherosclerosis[J]. Vnitrni Lekarstvi, 2019,64(12): 1142-1146.
[23] CHOI S K, PARK S, JANG S, et al. Cascade regulation of PPARgamma(2) and C/EBPalpha signaling pathways by celastrol impairs adipocyte differentiation and stimulates lipolysis in 3T3-L1 adipocytes[J]. Metabolism, 2016,65(5): 646-654.
[24] FARMER S R. Transcriptional control of adipocyte formation[J]. Cell Metab, 2006,4(4): 263-273.
[25] MAJDALAWIEH A, RO H S. PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1[J]. Nucl Recept Signal, 2010,8: e004.
[26] WU J S, KAO M H, TSAI H D, et al. Clinacanthus nutans mitigates neuronal apoptosis and ischemic brain damage through augmenting the C/EBPbeta-Driven PPAR-gamma transcription[J]. Mol Neurobiol, 2018, 55(7): 5425-5438.
[27] HONG W, PARK J, YUN W, et al. Inhibitory effect of celastrol on adipogenic differentiation of human adipose-derived stem cells[J]. Biochem Biophys Res Commun, 2018, 507(1-4):236-241.
[28] WANG T, WEI X J, WANG X G, et al. Effects of astragalus polysaccharides on the insulin sensitivity in the fat rats[J]. Chin Pharm J(中国药学杂志), 2011,46(3): 185-188.
[29] LI M, WU C, GUO H, et al. Mangiferin improves hepatic damage-associated molecular paternss lipid metabolic disorder and mitochondrial dysfunction in alcohol hepatitis tats[S]. Food Funct, 2019,10(6):3514-3534.
[30] SHI Y, ZHANG W, CHENG Y, et al. Bromide alleviates fatty acid-induced lipid accumulation in mouse primary hepatocytes through the activation of PPARalpha signals[J]. J Cell Mol Med, 2019, 23(6): 4464-4474.
[31] ZHANG X, WANG Y, GE H Y, et al. Celastrol reverses palmitic acid (PA)-caused TLR4-MD2 activation-dependent insulin resistance via disrupting MD2-related cellular binding to PA [J]. J Cell Physiol, 2018, 233(10): 6814-6824.
[32] GUAN Y, CUI Z J, SUN B, et al. Celastrol attenuates oxidative stress in the skeletal muscle of diabetic rats by regulating the AMPK-PGC1alpha-SIRT3 signaling pathway [J]. Int J Mol Med, 2016, 37(5): 1229-1238.
[33] ABU BAKAR M H, TAN J S. Improvement of mitochondrial function by celastrol in palmitate-treated C2C12 myotubes via activation of PI3K-Akt signaling pathway[J]. Biomed Pharmacother, 2017, 93: 903-912.
[34] KIM J E, LEE M H, NAM D H, et al. Celastrol, an NF-kappaB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice [J]. PLoS One, 2013, 8(4): e62068.
[35] KIM J, KWON J, KIM M, et al. Low-dielectric-constant polyimide aerogel composite films with low water uptake [J]. Polymer Journal, 2016, 48: 829-834.
[36] XU L, ZHAO W, WANG D, et al. Chinese medicine in the battle against obesity and metabolic diseases [J]. Front Physiol, 2018, 9(6): 850.
[37] SELL H, POITOU C, HABICH C, et al. Heat shock protein 60 in obesity: effect of bariatric surgery and its relation to inflammation and cardiovascular risk [J]. Obesity (Silver Spring, Md), 2017, 25(12): 2108-2114.
[38] ANCKAR J, SISTONEN L. Regulation of HSF1 function in the heat stress response: implications in aging and disease[J]. Annu Rev Biochem, 2011, 80: 1089-1115.
[39] MA X, XU L, AIBEROBELLO A T, et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1alpha transcriptional axis[J]. Cell Metab, 2015, 22(4): 695-708.
[40] WANG C, SHI C, YANG X, et al. Celastrol suppresses obesity process via increasing antioxidant capacity and improving lipid metabolism [J]. Eur J Pharmacol, 2014,744: 52-58.
[41] ZHANG J, SHAN J, CHEN X, et al. Celastrol mediates Th17 and Treg cell generation via metabolic signaling [J]. Biochem Biophys Res Commun, 2018, 497(3): 883-889.
[42] ESSER N, LEGRAND-POELS S, PIETTE J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes[J]. Diabetes Res Clin Pract, 2014, 105(2): 141-150.
[43] MACEDO F, DOS SANTOS L S, GLEZER I, et al. Brain innate immune response in diet-induced obesity as a paradigm for metabolic influence on inflammatory signaling [J]. Front Neur, 2019, 13: 342.
[44] LUO D, GUO Y, CHENG Y, et al. Natural product celastrol suppressed macrophage M1 polarization against inflammation in diet-induced obese mice via regulating Nrf2/HO-1, MAP kinase and NF-kappaB pathways[J]. Aging, 2017, 9(10): 2069-2082.
[45] FARZANEGI P, DANA A, EBRAHIMPOOR Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation[J]. Eur J Sport Sci, 2019,19(7):994-1003.
[46] GUO R, LIONG E C, SO K F, et al. Beneficial mechanisms of aerobic exercise on hepatic lipid metabolism in non-alcoholic fatty liver disease[J]. Hepatobiliary Pancreat Dis Int, 2015,14(2):139-144.
[47] ZHANG Y, GENG C, LIU X, et al. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1 [J]. Mol Metab, 2017, 6(1): 138-147.
[48] PFLUGER P T, HERRANZ D, VELASCO-MIGUEL S, et al. Sirt1 protects against high-fat diet-induced metabolic damage[J]. Proc Natl Acad Sci USA, 2008, 105(28): 9793-9798.